Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose escalation of Xeloda [capecitabine] or 5FU [fluorouracil] continuous infusion in combination with Taxotere [docetaxel] and concurrent once weekly, hypofractionated chest radiotherapy for advanced non small cell lung cancer: a phase I/II study.

Next Previous
X
Search
Trial Profile

Dose escalation of Xeloda [capecitabine] or 5FU [fluorouracil] continuous infusion in combination with Taxotere [docetaxel] and concurrent once weekly, hypofractionated chest radiotherapy for advanced non small cell lung cancer: a phase I/II study.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 24 Mar 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
    • 27 Feb 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top